Lipid-modifying agents, from statins to PCSK9 inhibitors: JACC focus seminar

Lipid-modifying agents, from statins to PCSK9 inhibitors: JACC focus seminar

Mendelian randomization studies and randomized trials have conclusively demonstrated that lower low-density lipoprotein (LDL) cholesterol results in fewer cardiovascular events. This review describes key stages in the evolution of LDL cholesterol–lowering treatment. Data from over 25 cardiovascular...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Preiss, D, Tobert, JA, Hovingh, GK, Reith, C
Formaat:	Journal article
Taal:	English
Gepubliceerd in:	Elsevier 2020

Gelijkaardige items

Lipid-modifying agents, from statins to PCSK9 inhibitors
door: Preiss, D, et al.
Gepubliceerd in: (2020)

LDL Cholesterol, Statins And PCSK 9 Inhibitors
door: Sanjiv Gupta
Gepubliceerd in: (2015-09-01)

United Kingdom Biobank (UK Biobank): JACC Focus Seminar 6/8
door: Caleyachetty, R, et al.
Gepubliceerd in: (2021)

PCSK9 Inhibitor Therapy as an Alternative for Statin Intolerance
door: K. O. Shnaider, et al.
Gepubliceerd in: (2023-12-01)

Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance
door: Konstantinos Koskinas, et al.
Gepubliceerd in: (2016-07-01)

Association of PCSK9 Inhibitor Initiation on Statin Adherence and Discontinuation
door: Christopher LaFratte, et al.
Gepubliceerd in: (2023-09-01)

Comparison of PCSK9 inhibitor evolocumab vs ezetimibe in statin-intolerant patients: Design of the goal achievement after utilizing an anti-PCSK9 antibody in statin-intolerant subjects 3 (GAUSS-3) trial
door: Nissen, SE, et al.
Gepubliceerd in: (2016)

COMPARISON OF QUALITY OF LIFE IN PATIENTS WITH PCSK9 INHIBITORS VS. STATIN INTOLERANCE
door: Mohsin Haseeb, et al.
Gepubliceerd in: (2023-03-01)

JACC: Asia
door: Jian'an Wang, MD, PhD
Gepubliceerd in: (2021-06-01)

JACC: Asia
door: Valentin Fuster, MD, PhD, et al.
Gepubliceerd in: (2021-06-01)

The PCSK9 decade
door: Gilles Lambert, et al.
Gepubliceerd in: (2012-12-01)

Plasma PCSK9 levels are significantly modified by statins and fibrates in humans
door: Mbikay Majambu, et al.
Gepubliceerd in: (2008-06-01)

Independent association of PCSK9 with platelet reactivity in subjects without statin or antiplatelet agents
door: Shuai Wang, et al.
Gepubliceerd in: (2022-10-01)

PCSK9 Inhibitor: Safe Alternative to Fill the Treatment Gap in Statin-Limited Conditions?
door: Ying Xiao, et al.
Gepubliceerd in: (2022-11-01)

PCSK9 inhibitors
door: Baris Gencer, et al.
Gepubliceerd in: (2015-04-01)

JACC: Case Reports
door: Julia Grapsa, MD, PhD, et al.
Gepubliceerd in: (2019-08-01)

JACC: Case Reports
door: Julia Grapsa, MD, PhD, et al.
Gepubliceerd in: (2020-06-01)

JACC: Case Reports
door: Purvi Parwani, MBBS, MPH, et al.
Gepubliceerd in: (2020-09-01)

Efficacy and safety of the PCSK9 inhibitor evolocumab in patients with mixed hyperlipidemia
door: Preiss, D, et al.
Gepubliceerd in: (2016)

PCSK9 Inhibitors: Focus on Evolocumab and Its Impact on Atherosclerosis Progression
door: Maram H. Abduljabbar
Gepubliceerd in: (2024-11-01)

Metabolomic consequences of genetic inhibition of PCSK9 compared with statin treatment
door: Sliz, E, et al.
Gepubliceerd in: (2018)

Vision for JACC: Case Reports
door: Julia Grapsa, MD, PhD
Gepubliceerd in: (2019-06-01)

Cholesteryl ester transfer protein inhibition for preventing cardiovascular events: JACC review topic of the week
door: Armitage, J, et al.
Gepubliceerd in: (2019)

PCSK9 Inhibitors in Clinical Practice: Experience of a Specialized Lipid Center
door: A. V. Blokhina, et al.
Gepubliceerd in: (2022-01-01)

Lipid lowering: PCSK9 inhibitors – new kids on the block target their breakthrough
door: Markus Mohaupt
Gepubliceerd in: (2016-07-01)

PCSK9 Inhibitors: The Evolving Future
door: Bijay Mukesh Jeswani, et al.
Gepubliceerd in: (2024-11-01)

Circulating Mature PCSK9 Level Predicts Diminished Response to Statin Therapy
door: Naoto Kuyama, et al.
Gepubliceerd in: (2021-06-01)

Introducing JACC: Basic to Translational Science
door: Douglas L. Mann, MD, et al.
Gepubliceerd in: (2016-01-01)

Case report: Intensive statin and PCSK-9 inhibitor combo reduces plaque volume and stenosis in ischemic stroke patient
door: Weiqi Zeng, et al.
Gepubliceerd in: (2023-08-01)

PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
door: Preiss, D, et al.
Gepubliceerd in: (2016)

Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study
door: Dennis T. Ko, et al.
Gepubliceerd in: (2018-11-01)

Role of PCSK9 inhibitors in the management of dyslipidaemia
door: Tiny Nair
Gepubliceerd in: (2024-03-01)

The Anti-Thrombotic Effects of PCSK9 Inhibitors
door: Martin Jozef Péč, et al.
Gepubliceerd in: (2023-08-01)

A Comprehensive Review of PCSK9 Inhibitors
door: Caroline Coppinger BS, et al.
Gepubliceerd in: (2022-05-01)

Cholesterol and stroke: role of PCSK9 inhibitors
door: L. Castilla-Guerra, et al.
Gepubliceerd in: (2019-04-01)

Effect of atorvastatin and rosuvastatin on the PCSK9 blood concentration in statin-naive patients with atherosclerosis
door: A. Yu. Filatova, et al.
Gepubliceerd in: (2019-06-01)

Pleiotropic Effects of PCSK9: Focus on Thrombosis and Haemostasis
door: Marianna Puccini, et al.
Gepubliceerd in: (2022-03-01)

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
door: Blom DJ, et al.
Gepubliceerd in: (2016-05-01)

Cardiovascular and safety events of PCSK9 inhibitors in statin-treated patients with cardiovascular risk: A Systematic Review and Meta-Analysis
door: Zinan ZHAO, et al.
Gepubliceerd in: (2020-10-01)

The New Face of Hyperlipidemia Management: Proprotein Convertase Subtilisin/Kexin Inhibitors (PCSK-9) and Their Emergent Role As An Alternative To Statin Therapy
door: Lillian Smith, et al.
Gepubliceerd in: (2016-03-01)